Novel Inhibitors of Plasmodium Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and In Vivo Efficacy in a Humanized Mouse Malaria Infection Model

Affiliations

• 1 Holistic Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
• 2 Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
• 3 Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria 0028, South Africa.
• 4 Holistic Drug Discovery and Development Centre (H3D), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
• 5 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, U.K.
• 6 Biological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee DD1 5EH, U.K.
• 7 Department of Microbiology and Immunology, Columbia University Medical Center, Hammer Health Sciences Center, 701 W. 168th Street, New York, New York 10032, United States.
• 8 Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States.
• 9 South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.
• 10 Department of Biochemistry, Stellenbosch University, Matieland, Stellenbosch 7601, South Africa.